Long-term follow-up of 38 patients with relapsed or refractory B-cell lymphoma given tisagenlecleucel (median 10.1 years): 10-year lymphoma-free survival 32% in large B-cell and 47% in follicular lymphoma; no relapses after 5.4 years, but 21% developed a second cancer.
RCTn = 38
Ruella et al. Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas